ATX inhibitor 1

CAS No. 2225892-70-4

ATX inhibitor 1( —— )

Catalog No. M22925 CAS No. 2225892-70-4

ATX inhibitor 1 is a potent ATX inhibitor (IC50: 1.23 nM, FS-3 and 2.18 nM, bis-pNPP).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 42 In Stock
5MG 38 In Stock
10MG 61 In Stock
25MG 123 In Stock
50MG 184 In Stock
100MG 305 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ATX inhibitor 1
  • Note
    Research use only, not for human use.
  • Brief Description
    ATX inhibitor 1 is a potent ATX inhibitor (IC50: 1.23 nM, FS-3 and 2.18 nM, bis-pNPP).
  • Description
    ATX inhibitor 1 is a potent ATX inhibitor (IC50: 1.23 nM, FS-3 and 2.18 nM, bis-pNPP).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    ATX
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2225892-70-4
  • Formula Weight
    501.3
  • Molecular Formula
    C21H23Cl2N2O6P
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (498.70 mM; Need ultrasonic)
  • SMILES
    O=P(O)(O)CC1=CC=C(NC(C2CCN(C(OCC3=CC(Cl)=CC(Cl)=C3)=O)CC2)=O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Balupuri A, et al. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation. Eur J Med Chem. 2018 Mar 25;148:397-409.
molnova catalog
related products
  • ONO-8430506

    ONO-8430506 is an orally available, potent autotaxin (ATX)/ENPP2 inhibitor (IC90: 100 nM) that inhibits ATX activity in mouse plasma.

  • PF‐04447943

    A potent, selective, brain penetrant, orally active PDE9A inhibitor with IC50 of 8.3 nM.

  • Tovinontrine

    Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment.